RxDoctor Payments Data

Brett Trockman, MD

Urology · Wheaton, ILNPI 1548279797

Payments from drug & device makers

$5,360in general payments, 2019–2025

Across 176 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Dendreon Pharmaceuticals LLC$429
  • Coloplast$371
  • Boston Scientific$308
  • Sumitomo Pharma America, Inc.$239
  • AbbVie$151
  • plus $2K from 28 others

What the payments were for

  • Consulting fees$1,90035%
  • Travel & lodging$401%
  • Food & beverage$3,41964%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,360 in reported general payments places this provider in the 65th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$431,207
Medicare patients
855
Services billed
15,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide57$852,400
MyrbetriqMirabegron268$259,431
OrgovyxRelugolix38$103,839
GemtesaVibegron102$88,713
Mirabegron ErMirabegron23$19,239
Tamsulosin Hcl754$13,752
Methenamine Hippurate193$12,256
Finasteride548$8,816
Potassium Citrate ErPotassium Citrate41$5,706
Estradiol49$2,537
Fosfomycin Tromethamine12$2,484
Silodosin22$2,465
Trimethoprim31$2,370
Bicalutamide52$2,356
Testosterone11$2,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$84$852,40057 claims
Astellas Pharma US IncMyrbetriq$43$259,431268 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$239$192,552140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 550 urology providers in Illinois.

Other urology in Wheaton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →